Trial Profile
Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2021
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 23 Nov 2021 Status changed from active, no longer recruiting to completed.
- 19 Oct 2021 Planned End Date changed from 13 Oct 2021 to 31 Dec 2021.
- 19 Oct 2021 Planned primary completion date changed from 13 Oct 2021 to 31 Dec 2021.